Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 5/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 3/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263551 | 0.93 | ENPP1 (0.37) | ENPP1DCTPP1POLBLMNAHTR4 | |
| SCHEMBL5261108 | 0.84 | CYP19A1 (0.39) | ENPP1POLBLMNAPDE4APDE4B | |
| SCHEMBL5262413 | 0.83 | POLB (0.33) | ENPP1DCTPP1POLBLMNATP53 | |
| SCHEMBL5262331 | 0.79 | CYP1A2 (0.35) | POLBLMNAKMT2A | |
| SCHEMBL5263136 | 0.79 | CYP1A2 (0.35) | POLBLMNAKMT2A | |
| SCHEMBL5263046 | 0.79 | CYP1A2 (0.35) | POLBLMNAKMT2A | |
| SCHEMBL5264790 | 0.78 | DCTPP1 (0.34) | DCTPP1POLBLMNAMEN1KMT2A | |
| SCHEMBL5266123 | 0.77 | MEN1 (0.50) | LMNAMEN1KMT2A | |
| SCHEMBL5263636 | 0.77 | IMPDH2 (0.37) | ENPP1POLBLMNAPDE4APDE4B | |
| SCHEMBL5264055 | 0.76 | DPP4 (0.37) | ENPP1DCTPP1POLBLMNAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | ENPP1 3609/4885DCTPP1 3859/4885POLB 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.